Rheos Medicines is a biopharmaceutical company developing novel medicines that modulate immune cell metabolism with an initial focus on treating patients with severe immune-mediated diseases.
Launched in 2018 by Third Rock Ventures and pioneers in the field, Rheos is built on groundbreaking science, and we have assembled an experienced and passionate team of scientists, drug developers, and industry- leading advisors to advance a novel pipeline of drugs.
Transforming immunometabolism for AI and Inflammation
We are rapidly applying a first-in-field approach in immunometabolism with a comprehensive, systems-biology understanding of the metabolic pathways that drive immune cell function. This knowledgebase allows Rheos to identify and advance a powerful new class of medicines, and to understand the specific aberrations that drive immune-mediated disease.
The metabolic activity of immune cells is a critical network of interactions that play a central role in determining immune cell fate and function. Dysregulation of this network is central to the development of autoimmune disease, and understanding the differences in immunometabolism between patients offers critical insights into the biology of these diseases. Intervening in metabolic pathways has the potential to be a powerful lever for both developing therapies and segmenting diseases.
We have brought together pioneering scientists, leading clinicians, and an experienced leadership team to advance new and powerful medicines through discovery and into the clinic.